Literature DB >> 26681783

Noninvasive Tests for Inflammatory Bowel Disease: A Meta-analysis.

Gea A Holtman1, Yvonne Lisman-van Leeuwen1, Johannes B Reitsma2, Marjolein Y Berger3.   

Abstract

BACKGROUND: The clinical presentation of pediatric inflammatory bowel disease (IBD) is often nonspecific and overlaps with functional gastrointestinal disorders.
OBJECTIVE: To determine the diagnostic accuracy of symptoms, signs, noninvasive tests, and test combinations that can assist the clinician with the diagnosis of IBD in symptomatic children.
METHODS: A literature search was conducted of Medline and Embase. Two reviewers independently selected studies reporting on the diagnostic accuracy of tests for IBD, with confirmation by endoscopy and histopathology or clinical follow-up, in children with chronic gastrointestinal symptoms. Two reviewers independently extracted data and assessed study quality with the QUADAS-2, an evidence-based quality assessment tool for diagnostic accuracy studies.
RESULTS: Nineteen studies were included (N = 2806). Symptoms (abdominal pain, diarrhea, rectal bleeding, and weight loss) had pooled sensitivities ranging from 0.48 to 0.82 and specificities ranging from 0.17 to 0.78. Of all the blood markers, C-reactive protein (CRP) (9 studies) and albumin (6 studies) had the best performance, with pooled sensitivities of 0.63 (0.51-0.73) and 0.48 (0.31-0.66), respectively, and specificities of 0.88 (0.80-0.93) and 0.94 (0.86-0.98). Assessment of fecal calprotectin (FCal) (10 studies) had a pooled sensitivity of 0.99 (0.92-1.00) and a specificity of 0.65 (0.54-0.74). One limitation was that none of the studies was conducted in nonreferred children.
CONCLUSIONS: In children whose pediatrician is considering an endoscopy, symptoms are not accurate enough to identify low-risk patients in whom an endoscopy can be avoided. FCal, CRP, and albumin findings are potentially of clinical value, given their ability to select children at low risk (negative FCal test result) or high risk (positive CRP or albumin test result) for IBD.
Copyright © 2016 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2015        PMID: 26681783     DOI: 10.1542/peds.2015-2126

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

1.  Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.

Authors:  Gea A Holtman; Yvonne Lisman-van Leeuwen; Boudewijn J Kollen; Obbe F Norbruis; Johanna C Escher; Angelika Kindermann; Yolanda B de Rijke; Patrick F van Rheenen; Marjolein Y Berger
Journal:  Ann Fam Med       Date:  2016-09       Impact factor: 5.166

Review 2.  Diagnosis and management of inflammatory bowel disease in children.

Authors:  Stephanie B Oliveira; Iona M Monteiro
Journal:  BMJ       Date:  2017-05-31

3.  Use of Laboratory Markers in Addition to Symptoms for Diagnosis of Inflammatory Bowel Disease in Children: A Meta-analysis of Individual Patient Data.

Authors:  Gea A Holtman; Yvonne Lisman-van Leeuwen; Andrew S Day; Ulrika L Fagerberg; Paul Henderson; Stevan T Leach; Gøri Perminow; David Mack; Patrick F van Rheenen; Els van de Vijver; David C Wilson; Johannes B Reitsma; Marjolein Y Berger
Journal:  JAMA Pediatr       Date:  2017-10-01       Impact factor: 26.796

4.  Fecal Calprotectin Is Elevated in HIV and Related to Systemic Inflammation.

Authors:  Allison Ross Eckard; Heather Y Hughes; Nancy L Hagood; Mary Ann O'Riordan; Danielle Labbato; Julia C Kosco; Sarah E Scott; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2021-02-01       Impact factor: 3.771

5.  Selecting children with suspected inflammatory bowel disease for endoscopy with the calgranulin C or calprotectin stool test: protocol of the CACATU study.

Authors:  Anke Heida; Els Van de Vijver; Anneke Muller Kobold; Patrick van Rheenen
Journal:  BMJ Open       Date:  2017-05-29       Impact factor: 2.692

6.  Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease.

Authors:  Cristiane C Otoni; Romy M Heilmann; Mercedes García-Sancho; Angel Sainz; Mark R Ackermann; Jan S Suchodolski; Jörg M Steiner; Albert E Jergens
Journal:  J Vet Intern Med       Date:  2018-04-06       Impact factor: 3.333

7.  Predicting inflammatory bowel disease in children with abdominal pain and diarrhoea: calgranulin-C versus calprotectin stool tests.

Authors:  Anke Heida; Els Van de Vijver; Don van Ravenzwaaij; Stephanie Van Biervliet; Thalia Z Hummel; Zehre Yuksel; Gieneke Gonera-de Jong; Renate Schulenberg; Anneke Muller Kobold; Patrick Ferry van Rheenen
Journal:  Arch Dis Child       Date:  2018-03-07       Impact factor: 3.791

8.  Analytical and clinical performance of the fully-automated LIAISONXL calprotectin immunoassay from DiaSorin in IBD patients.

Authors:  R Vicente-Steijn; J M Jansen; R Bisheshar; I-A Haagen
Journal:  Pract Lab Med       Date:  2020-06-24

9.  Diagnostic test strategies in children at increased risk of inflammatory bowel disease in primary care.

Authors:  Gea A Holtman; Yvonne Lisman-van Leeuwen; Boudewijn J Kollen; Obbe F Norbruis; Johanna C Escher; Laurence C Walhout; Angelika Kindermann; Yolanda B de Rijke; Patrick F van Rheenen; Marjolein Y Berger
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

10.  Biomarker discovery in inflammatory bowel diseases using network-based feature selection.

Authors:  Mostafa Abbas; John Matta; Thanh Le; Halima Bensmail; Tayo Obafemi-Ajayi; Vasant Honavar; Yasser El-Manzalawy
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.